Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.62 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.60 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.60 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021086 | 0.90 | NOTUM (0.69) | NOTUMTP53HSD17B3ALDH1A1IDO1 | |
| SCHEMBL397314 | 0.90 | NOTUM (0.69) | NOTUMTP53HSD17B3ALDH1A1IDO1 | |
| SCHEMBL29620859 | 0.88 | NOTUM (0.62) | NOTUMPDK1PDK2PDK3PDK4 | |
| SCHEMBL594384 | 0.88 | NOTUM (0.62) | NOTUMPDK1PDK2PDK3PDK4 | |
| SCHEMBL28498038 | 0.86 | PDK1 (0.61) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL8231436 | 0.85 | CYP11B1 (0.56) | NOTUMTP53HSD17B3ALDH1A1LMNA | |
| SCHEMBL19657374 | 0.84 | PDK1 (0.53) | NOTUMPDK1PDK2PDK3PDK4 | |
| SCHEMBL5413736 | 0.84 | KDM4E (0.72) | PDK1PDK2PDK3PDK4TSHR | |
| SCHEMBL30039800 | 0.84 | KDM4E (0.72) | PDK1PDK2PDK3PDK4TSHR | |
| SCHEMBL29082759 | 0.83 | PDK1 (0.59) | PDK1PDK2PDK3PDK4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | claimed |
| EP-2421824-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| WO-2010124114-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-4495353-A | ETHERIFICATION OF A HALOAROMTIC COMPOUND | STERLING DRUG INC. (US) | 1985-01-22 | — | — | US | claimed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-112312899-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | US | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| US-4495353-A | ETHERIFICATION OF A HALOAROMTIC COMPOUND | STERLING DRUG INC. (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0057321-B1 | PROCESSES FOR SUBSTITUTION OF AROMATIC ORGANIC COMPOUNDS | STERWIN AG. (CH) | 1984-03-21 | — | — | EP | disclosed |
| US-4422955-A | REPLACING HALOGEN ATOM ATTACHED TO RING WITH ALKOXY-TYPE SUBSTITUENT USING AS CATALYST A FORMIC ACID ESTER AND A CUPROUS SALT | STERLING DRUG INC. (US) | 1983-12-27 | — | — | US | disclosed |
| EP-0057321-A1 | Processes for substitution of aromatic organic compounds | STERWIN AG. (CH) | 1982-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | NOTUM 4253/4885PDK1 2126/4885PDK2 1144/4885 |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA3, ADORA1 | NOTUM 4253/4885PDK1 2126/4885PDK2 1144/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | NOTUM 173/4885PDK1 910/4885PDK2 1522/4885 |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | HRH4, HNMT, NNT | NOTUM 1218/4885PDK1 2750/4885PDK2 2991/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | NOTUM 2860/4885PDK1 811/4885PDK2 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.